Jon Carl Serbousek - 05 Jan 2023 Form 4 Insider Report for Orthofix Medical Inc. (OFIX)

Role
Executive Chairman, Director
Signature
/s/ Patrick Keran, attorney-in-fact
Issuer symbol
OFIX
Transactions as of
05 Jan 2023
Net transactions value
$0
Form type
4
Filing time
09 Jan 2023, 18:08:13 UTC
Previous filing
03 Nov 2022
Next filing
03 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OFIX Common Stock Award $0 +45,872 +24% $0.000000 235,379 05 Jan 2023 Direct F1
transaction OFIX Common Stock Award $0 +40,764 +17% $0.000000 276,143 05 Jan 2023 Direct F2
transaction OFIX Common Stock Award $0 +81,967 +30% $0.000000 358,110 05 Jan 2023 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents outstanding performance stock units for awards granted in 2020, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on June 8, 2023.
F2 Represents outstanding performance stock units for awards granted in 2021, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on April 1, 2024.
F3 Represents outstanding performance stock units for awards granted in 2022, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on January 31, 2025.
F4 Includes 307,621 unvested restricted stock units.